Fidelity Investments’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$297M Buy
12,452,199
+543,061
+5% +$15.1M 0.02% 693
2025
Q4
$330M Buy
11,909,138
+216,285
+2% +$5.52M 0.02% 664
2025
Q3
$284M Sell
11,692,853
-1,268,606
-10% -$25.2M 0.01% 709
2025
Q2
$220M Buy
12,961,459
+5,041,406
+64% +$87.8M 0.01% 777
2025
Q1
$155M Buy
7,920,053
+4,602,759
+139% +$121M 0.01% 915
2024
Q4
$82.3M Sell
3,317,294
-894,223
-21% -$22.8M ﹤0.01% 1191
2024
Q3
$103M Sell
4,211,517
-196,178
-4% -$5.07M 0.01% 1087
2024
Q2
$103M Sell
4,407,695
-486,758
-10% -$12M 0.01% 1027
2024
Q1
$162M Sell
4,894,453
-1,285,869
-21% -$40.1M 0.01% 872
2023
Q4
$168M Sell
6,180,322
-317,509
-5% -$7.89M 0.01% 817
2023
Q3
$156M Sell
6,497,831
-639,878
-9% -$17.2M 0.01% 798
2023
Q2
$228M Buy
7,137,709
+1,050,156
+17% +$34.1M 0.02% 671
2023
Q1
$186M Buy
6,087,553
+1,121,564
+23% +$44.3M 0.02% 737
2022
Q4
$194M Buy
4,965,989
+381,854
+8% +$17.1M 0.02% 696
2022
Q3
$218M Sell
4,584,135
-215,964
-4% -$12.3M 0.02% 628
2022
Q2
$186M Sell
4,800,099
-614,997
-11% -$24.4M 0.02% 718
2022
Q1
$310M Buy
5,415,096
+1,493,793
+38% +$98M 0.02% 620
2021
Q4
$312M Sell
3,921,303
-2,863
-0.1% -$245K 0.02% 629
2021
Q3
$341M Sell
3,924,166
-3,761,094
-49% -$378M 0.03% 575
2021
Q2
$989M Buy
7,685,260
+1
+0% +$80 0.08% 231
2021
Q1
$615M Buy
7,685,259
+356,673
+5% +$33.9M 0.05% 361
2020
Q4
$598M Hold
7,328,586
0.05% 351
2020
Q3
$180M Buy
7,328,586
+356,674
+5% +$8.85M 0.02% 667
2020
Q2
$195M Hold
6,971,912
0.02% 622
2020
Q1
$125M Buy
+6,971,912
New +$152M 0.02% 678

Other funds holding BEAM

Fidelity Investments's BEAM Position: Q1 2026 in Review

Fidelity Investments increased its Beam Therapeutics (BEAM) stake by 4.6% in Q1 2026, buying an estimated $15.1M and bringing the position to 12,452,199 shares worth $297M. The position accounts for 0.02% of the portfolio, ranked #693.

Fidelity Investments first reported a position in BEAM in Q1 2020 and has held it in 25 quarters since. The position peaked at $989M in Q2 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Fidelity Investments held 12,452,199 shares of Beam Therapeutics worth $297M as of Q1 2026.
  • Fidelity Investments bought 543,061 Beam Therapeutics shares in Q1 2026, an estimated $15.1M.
  • Beam Therapeutics made up 0.02% of Fidelity Investments's portfolio in Q1 2026, its #693 holding.
  • Fidelity Investments first reported a position in Beam Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Fidelity Investments's Beam Therapeutics position peaked at $989M in Q2 2021.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.